Department of Colon & Rectal Surgery, William Beaumont Hospital, Royal Oak, Michigan, USA.
Inflamm Bowel Dis. 2012 Mar;18(3):506-12. doi: 10.1002/ibd.21739. Epub 2011 May 3.
The role of endoluminal stenting in benign obstruction, especially for Crohn's disease (CD), is controversial, with limited data and widely disparate outcomes. The purpose of this study was to determine the long-term efficacy and safety of this technology in the treatment of fibrostenotic CD and to review the existing literature on this topic.
We undertook a retrospective review of all patients undergoing endoluminal stenting for CD strictures at our institution from 2001 to 2010. Outcome measures included technical success, clinical improvement, duration of stent and luminal patency, and need for re-intervention.
Five patients underwent this procedure with a 100% rate of technical and an 80% rate of clinical success. Mean follow-up was 28 months (range 3 weeks to 109 months) and mean long-term luminal patency was 34.8 months (range 4.5-109 months). There was one complication involving reobstruction which required surgical intervention and no mortalities.
Endoluminal stenting of CD strictures is a safe and effective alternative to surgery which can provide lasting benefit in select patients. Further studies are necessary to clarify the full impact of this technology on long-term management of this complex disease.
腔内支架置入术在良性梗阻中的作用，尤其是在克罗恩病（CD）中，存在争议，相关数据有限，且结果差异较大。本研究旨在确定该技术在治疗纤维狭窄性 CD 中的长期疗效和安全性，并回顾该主题的现有文献。
我们对 2001 年至 2010 年期间在我院接受 CD 狭窄腔内支架置入术的所有患者进行了回顾性分析。主要观察指标包括技术成功率、临床改善、支架和管腔通畅时间以及需要再次干预的情况。
5 例患者接受了该手术，技术成功率为 100%，临床成功率为 80%。平均随访时间为 28 个月（3 周至 109 个月），平均长期管腔通畅时间为 34.8 个月（4.5-109 个月）。有 1 例并发症为再梗阻，需要手术干预，无死亡病例。
腔内支架置入术是一种安全有效的手术替代方法，可在某些患者中提供持久的益处。需要进一步的研究来阐明该技术对这种复杂疾病的长期管理的全面影响。
